AEON Biopharma (AEON) Accounts Payables (2020 - 2026)
AEON Biopharma (AEON) posted Accounts Payables of $942000.0 for Q4 2025, down 62.69% sequentially from $2.5 million in Q3 2025, and down 84.06% YoY from $5.9 million in Q4 2024.
AEON Biopharma (AEON) Accounts Payables (2020 - 2026) Analysis & Trends
AEON Biopharma has reported Accounts Payables for 6 years, with the latest figure at $942000.0 in Q4 2025.
- Quarterly Accounts Payables fell 84.06% year-over-year to $942000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $942000.0 (down 84.06% YoY) and the FY2025 annual result came in at $942000.0, down 84.06% from the prior year.
- Accounts Payables retreated to $942000.0 in Q4 2025 per AEON's latest filing, from $2.5 million in the prior quarter.
- Over five years, Accounts Payables peaked at $7.8 million in Q4 2022 and troughed at $70000.0 in Q3 2021.
- A 5-year average of $3.1 million and a median of $3.0 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2021 and 2025: Accounts Payables soared 2921.83% in 2021, then sank 84.06% in 2025.
- Over 5 years, Accounts Payables stood at $634585.0 in 2021, then soared by 1129.94% to $7.8 million in 2022, then tumbled by 56.59% to $3.4 million in 2023, then surged by 74.44% to $5.9 million in 2024, then slumped by 84.06% to $942000.0 in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $942000.0, $2.5 million, and $3.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 35.57 Mn |
| 10 | AEON Biopharma | 9.85 Mn | 6.42 Mn | - | 2.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.70 Mn |
| Dec 31, 2025 | 942,000.00 |
| Sep 30, 2025 | 2.53 Mn |
| Jun 30, 2025 | 3.91 Mn |
| Mar 31, 2025 | 2.44 Mn |
| Dec 31, 2024 | 5.91 Mn |
| Sep 30, 2024 | 4.63 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Mar 31, 2024 | 6.52 Mn |
| Dec 31, 2023 | 3.39 Mn |
| Sep 30, 2023 | 4.01 Mn |
| Jun 30, 2023 | 6.96 Mn |
| Mar 31, 2023 | 3.98 Mn |
| Dec 31, 2022 | 7.81 Mn |
| Sep 30, 2022 | 943,789.00 |
| Jun 30, 2022 | 848,813.00 |
| Mar 31, 2022 | 741,843.00 |
| Dec 31, 2021 | 634,585.00 |
| Sep 30, 2021 | 70,000.00 |
| Jun 30, 2021 | 102,950.00 |